Kanamycin: Difference between revisions

(Kanamycin page)
 
(Text replacement - "Category:Drugs" to "Category:Pharmacology")
Line 57: Line 57:
==References==
==References==
<UpToDate, MicroMedex/>
<UpToDate, MicroMedex/>
[[Category:Drugs]]
[[Category:Pharmacology]]

Revision as of 15:53, 22 March 2016

Administration

  • Type: Aminoglycoside
  • Dosage Forms: 1 g/3 mL
  • Routes of Administration: IM, IV

Black Box Warnings

  • Neurotoxicity/Ototoxicity
    • Increased risk with renal impairment, high dose, prolonged tx
  • Nephrotoxicity
    • Increased risk with renal impairment, high dose, prolonged tx
    • Monitor renal function, peak/trough levels
  • Neuromuscular Blockade
    • Risk of respiratory paralysis possible with any route of administration

Adult Dosing

  • Bacterial Infections: 7.5 mg/kg IM/IV q12h
    • For obese patients, use adjusted wt of IBW + 0.4 x (ABW - IBW)
    • Adjust dose based on serum levels

Pediatric Dosing

  • Bacterial Infections: 7.5 mg/kg IM/IV q12h

Special Populations

  • Pregnancy Risk Factor: D

Renal Dosing

  • CrCl 50-80: give q12-24h
  • CrCl 10-50: give q24-72h
  • CrCl <10: give q48-72h

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

  • Nephrotoxicity
  • Ototoxicity, auditory
  • Ototoxicity, vestibular
  • Neurotoxicity
  • Neuromuscular blockade

Common

  • Hearing loss
  • Tinnitus
  • Vertigo
  • BUN, Cr elevated

Pharmacology

  • Half-life: 2-4 hrs
  • Metabolism: CYP 450
  • Excretion: Urine

Mechanism of Action

  • Interferes with protein synthesis in bacterial cell by binding to ribosomal subunit

References

<UpToDate, MicroMedex/>